Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Shelton Capital Management

Shelton Capital Management reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 76.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,012 shares of the life sciences company’s stock after selling 20,049 shares during the quarter. Shelton Capital Management’s holdings in Illumina were worth $803,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. WCM Investment Management LLC raised its stake in Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after acquiring an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after acquiring an additional 27,618 shares during the last quarter. Geode Capital Management LLC raised its stake in Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after acquiring an additional 48,018 shares during the last quarter. Norges Bank purchased a new stake in Illumina during the 4th quarter valued at approximately $228,714,000. Finally, Pictet Asset Management Holding SA raised its stake in Illumina by 245.7% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company’s stock valued at $158,011,000 after acquiring an additional 840,423 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and dropped their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Citigroup dropped their target price on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday. Royal Bank of Canada dropped their target price on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $139.85.

Illumina Stock Up 8.5 %

NASDAQ ILMN opened at $76.30 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a 50-day simple moving average of $90.77 and a 200 day simple moving average of $123.08. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The stock has a market cap of $12.09 billion, a PE ratio of -9.93, a PEG ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.